Market Crash: 2 Healthcare Stocks Worth Loading Up on at a Discount

The article highlights two healthcare names trading at valuation discounts: Intuitive Surgical at 45x forward earnings, down from 60x earlier this year, and Abbott at 17x forward earnings, down from more than 22x. Intuitive posted 19% revenue growth and 17% growth in Da Vinci procedures, while Abbott’s diversified business and Dividend King status support long-term appeal. The piece is broadly constructive on both stocks, but it is mainly opinion/valuation commentary rather than fresh company-specific news.

Analysis

The key second-order dynamic is not simply that both names are high-quality franchises, but that the recent pullback compresses very different types of duration risk. ISRG is still a multiple-sensitive compounder where near-term procedure acceleration mostly matters because it de-risks the long runway; ABT is more of a cash-flow compounding and capital-return vehicle where the setup is driven by rate expectations and defensive rotation. In other words, the market is paying less for growth and still paying up for quality, but ISRG’s multiple is far more vulnerable to any slip in procedure momentum than ABT’s is to a modest earnings miss.

For ISRG, the real catalyst is not just system sales but installed-base utilization. Higher procedure growth creates a flywheel in instruments and accessories, which can out-earn consensus if utilization keeps compounding in the mid-teens; conversely, any slowdown in elective procedure volumes would show up first in recurring revenue, not headline unit sales. The competitive risk is less about direct share loss today and more about future hospital procurement behavior: if capital budgets tighten, the market can delay new robot purchases while still using the current fleet longer, which caps near-term upside despite strong brand inertia.

ABT’s advantage is that it has more ways to disappoint slowly and fewer ways to break quickly. The dividend and diversification likely anchor the stock in risk-off tape, but the better trade is to view it as a defensive growth substitute rather than a pure income name: if rates drift lower, the multiple can re-rate without needing an earnings inflection. The market may be underestimating how much of ABT’s downside is already washed out, but also overestimating how much upside can come from a single business line; the stock should grind, not gap, unless diagnostics or devices accelerate materially.

The contrarian takeaway is that both names look more attractive as relative longs than outright momentum buys. ISRG’s valuation reset creates a cleaner entry for investors willing to wait 12-24 months for compounding to reassert itself, while ABT is better as a low-volatility ballast that can absorb macro noise. If the market broadens beyond mega-cap AI and into healthcare quality, these names should outperform on multiple support rather than explosive EPS revisions.

Key Decisions for Investors

• Long ISRG on any additional 5-7% pullback over the next 2-4 weeks; target a 12-18 month hold for multiple recovery if procedure growth remains mid-teens, with downside mainly tied to elective-volume deceleration.
• Use ABT as a defensive quality long versus high-multiple cyclicals: buy on market weakness and hold 6-12 months for yield-plus-growth compounding; risk/reward is asymmetric because the dividend and diversified cash flows limit drawdown.
• Pair trade: long ABT / short a higher-beta healthcare or broad-growth ETF into any risk-off tape; the setup benefits from lower rates and defensive rotation, with ABT’s lower earnings volatility offering cleaner relative performance.
• For ISRG, consider a call spread rather than common stock if you want upside on sustained utilization growth but want to cap valuation risk; use a 9-15 month horizon since the rerating will likely be slower than the fundamental compounding.
• Avoid chasing either name after a sharp relief rally; both are better bought on macro-driven de-rates than after product-news spikes, because the edge comes from valuation reset, not one-quarter earnings beats.